(Q34636437)

English

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Jonathan W Goldman

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert N Raju

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gregory A Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Iman El-Hariry

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Florentina Teofilivici

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Vojo M Vukovic

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert Bradley

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Michael D Karol

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Yu Chen

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Wei Guo

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Takayo Inoue

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lee S Rosen

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

25 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

152

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-13-152

0 references

The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

HSP90 as a platform for the assembly of more effective cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Hsp90 molecular chaperone inhibitors: are we there yet?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Geldanamycin inhibits TGF-beta signaling through induction of Hsp70.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Hsp90 and co-chaperones twist the functions of diverse client proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Radicicol but not geldanamycin evokes oxidative stress response and efflux protein inhibition in ARPE-19 human retinal pigment epithelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Organizing cell renewal in the intestine: stem cells, signals and combinatorial control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Hsp70 chaperones: cellular functions and molecular mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626541

7 July 2018

Growth of intestinal epithelium in organ culture is dependent on EGF signalling

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-152

21 January 2018

EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem/progenitor cells in long-term monolayer cell culture.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-152

21 January 2018

Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-152

21 January 2018

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23530663

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-13-152

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34636437&oldid=1557576537"